AVDL - Avadel Pharmaceuticals plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$21.43
DETAILS
HIGH:
$30.00
LOW:
$18.50
MEDIAN:
$20.00
CONSENSUS:
$21.43
DOWNSIDE:
0.97%
About Avadel Pharmaceuticals plc (https://investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc)
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Gregory J. Divis Jr. | Chief Executive Officer & Director | 1967 | $677,400 USD |
| Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer | 1974 | $634,700 USD |
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer | 1965 | $530,119 USD |
| Angie Woods | Vice President of People & Culture | – | – |
| Gregory J. Davis | Vice President of Corporate and Business Development | 1965 | – |
| Jason Vaughn | Senior Vice President of Technical Operations | – | – |
| Jennifer Gudeman | Senior Vice President of Medical & Clinical Affairs | – | – |
| Marla Scarola | Senior Vice President of Regulatory & Quality | – | – |
| Polly A. Murphy | Chief Business Officer | 1965 | – |
| Susan Rodriguez | Chief Operating Officer | 1965 | – |